When we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was still reeling from its post-pandemic crash. “I didn’t expect Yosemite to be moving this fast,” he said. Now, the venture outfit has a team of 17; a cluster of blockbuster drugs are all losing patent protection in roughly the same window, creating all kinds of new opportunities; and AI has gone from a curiosity to, in Jobs’s words, a huge part of what Yosemite does. .
Reed Jobs would rather talk about curing cancer than his last name.
